Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.60 |
| ▸ | HTR2A | P28223 | 5/20 | 0.60 |
| ▸ | HTR2C | P28335 | 5/20 | 0.60 |
| ▸ | DRD3 | P35462 | 5/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.60 |
| ▸ | DRD1 | P21728 | 3/20 | 0.60 |
| ▸ | HRH1 | P35367 | 3/20 | 0.60 |
| ▸ | DRD4 | P21917 | 2/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.60 |
| ▸ | HTR2B | P41595 | 2/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.60 |
| ▸ | HTR3A | P46098 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8007974 | 1.00 | DRD2 (0.60) | DRD2HTR2AHTR2CDRD3ADRA2A | |
| SCHEMBL2006845 | 0.90 | HTR2A (0.56) | DRD2HTR2AHTR2CDRD3ADRA2A | |
| SCHEMBL8002261 | 0.90 | HTR2A (0.56) | DRD2HTR2AHTR2CDRD3ADRA2A | |
| SCHEMBL12503725 | 0.87 | DRD2 (0.43) | DRD2HTR2AHTR2CDRD3ADRA2A | |
| SCHEMBL12413267 | 0.85 | HTR2A (0.64) | DRD2HTR2AHTR2CDRD3ADRA2A | |
| SCHEMBL8002235 | 0.83 | DRD2 (0.61) | DRD2HTR2AHTR2CDRD3ADRA2A | |
| SCHEMBL2006925 | 0.83 | DRD2 (0.61) | DRD2HTR2AHTR2CDRD3ADRA2A | |
| SCHEMBL12413270 | 0.83 | HTR2A (0.56) | DRD2HTR2AHTR2CDRD3ADRA2A | |
| SCHEMBL2003487 | 0.81 | DRD2 (0.67) | DRD2HTR2AHTR2CDRD3ADRA2A | |
| SCHEMBL8006670 | 0.81 | DRD2 (0.67) | DRD2HTR2AHTR2CDRD3ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240492-B1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | ORGANON NV (NL) | 2011-10-05 | — | — | EP | disclosed |
| US-20110166363-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-07-07 | — | — | US | disclosed |
| US-7964739-B2 | Through a stilbene derivative, to a pyrrolidine intermediate, followed by cyclization; asenapine is an antipsychotic agent; industrial scale | N.V. ORGANON (NL) | 2011-06-21 | — | — | US | disclosed |
| US-7964739-B2 | Through a stilbene derivative, to a pyrrolidine intermediate, followed by cyclization; asenapine is an antipsychotic agent; industrial scale | N.V. ORGANON (NL) | 2011-06-21 | — | — | US | disclosed |
| US-7964739-B2 | Through a stilbene derivative, to a pyrrolidine intermediate, followed by cyclization; asenapine is an antipsychotic agent; industrial scale | N.V. ORGANON (NL) | 2011-06-21 | — | — | US | disclosed |
| EP-2240492-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | N.V. Organon (NL) | 2010-10-20 | — | — | EP | disclosed |
| US-20090227803-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | N.V. ORGANON | 2009-09-10 | — | — | US | disclosed |
| US-20090227803-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | N.V. ORGANON | 2009-09-10 | — | — | US | disclosed |
| US-20090227803-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | N.V. ORGANON | 2009-09-10 | — | — | US | disclosed |
| WO-2009087058-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | N.V. ORGANON (NL) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166363-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | DHPS, CYP3A5, PNMT | DRD2 22/4885HTR2A 104/4885HTR2C 25/4885 |
| US-20090227803-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | DHPS, CYP3A5, PNMT | DRD2 22/4885HTR2A 104/4885HTR2C 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.